Seaport Therapeutics is building a fail-safe into its Phase 2b depression trial.

The biotech is testing its drug, called SPT-300, in patients with major depressive disorder. But executives believe SPT-300 could prove more promising in …

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844